CAS.NO: 204656-20-2
Biocon Liraglutide can reduce glycosylated hemoglobin, and it has been shown to be beneficial to cardiovascular treatment in typeⅡ diabetic patients with atherosclerotic cardiovascular disease with coronary heart disease, ischemic stroke, and peripheral artery disease.
| Product Name | Liraglutide |
| Packing Specification | 10g/100g/500g |
| Appearances | White or off-white powder |
| Activity: NLT 10Unit/mg | 70%~130% |
| Content | 95.0%~105.0% |
| Bacterial Endotoxin | Less than 10 EU/mg |
| Residual HCP | NMT 10ng/mg |
| Residual Exogenous DNA | NMT 10ng/dose |
| Macromolecular Potein | NMT 0.7% |
| HPLC Purity | ＞98.0% |
| Storage Conditions | -15℃ below, protected from light, sealed. |
The data should be subject to test report of products.
Used to prepare liraglutide injection.
Liraglutide easy dissolved in acidic (pH < 2.5), neutral and alkaline conditions, and can be dissolved and clarified above pH7.0.
Transportation stability: It is transported in an ice pack to keep it active.
Storage stability: The product can be stored for at least 24 months at -15°C below.
Pollution should be avoided during operation.
The product should not be used for diagnosis or treatment of animals or humans.
